149 related articles for article (PubMed ID: 12942419)
1. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT
Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
Kearney BP; Sayre JR; Flaherty JF; Chen SS; Kaul S; Cheng AK
J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710
[TBL] [Abstract][Full Text] [Related]
4. Effect of tenofovir on didanosine absorption in patients with HIV.
Pecora Fulco P; Kirian MA
Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir drug interactions: ddI and d4T.
TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
[No Abstract] [Full Text] [Related]
6. Tenofovir and didanosine: a dangerous liaison.
Waters L; Maitland D; Moyle GJ
AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
[No Abstract] [Full Text] [Related]
7. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
[TBL] [Abstract][Full Text] [Related]
8. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Kirian MA; Higginson RT; Fulco PP
Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
[TBL] [Abstract][Full Text] [Related]
9. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.
Murphy MD; O'Hearn M; Chou S
Clin Infect Dis; 2003 Apr; 36(8):1082-5. PubMed ID: 12684925
[TBL] [Abstract][Full Text] [Related]
10. French investigators warn of LPV/TDF/ddI interaction.
Carter M
IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
[No Abstract] [Full Text] [Related]
11. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Barreiro P; Soriano V
J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.
TreatmentUpdate; 2002 Aug; 14(6):5. PubMed ID: 12238451
[No Abstract] [Full Text] [Related]
15. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
16. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
Ripamonti D; Maggiolo F; Suter F
AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107
[No Abstract] [Full Text] [Related]
17. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
[TBL] [Abstract][Full Text] [Related]
18. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Negredo E; Garrabou G; Puig J; Lòpez S; Morén C; Bellido R; Ayen R; Cardellach F; Miró O; Clotet B
Antivir Ther; 2008; 13(2):231-40. PubMed ID: 18505174
[TBL] [Abstract][Full Text] [Related]
19. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
[No Abstract] [Full Text] [Related]
20. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
